Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

US mRNA specialist Moderna (Nasdaq: MRNA) has announced that its manufacturing facility in the UK has been granted a manufacturer’s license by the Medicines and Healthcare products Regulatory Agency ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

The FDA will remove industry representatives from advisory committees and replace them with patients and caregivers ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...

In a report released today, Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to ...

What Happened? A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Arexvy and Abrysvo are approved to prevent RSV-associated lower respiratory tract disease in adults aged 50 to 59 and 18 to ...